KMDA Kamada Ltd.
USHealthcareAs of 2026-07-10 16:00
Why KMDA matters now
Kamada Ltd. (KMDA) is a US stock in Healthcare. The latest InvestLog snapshot shows $7.12 with -0.42% on the session and $410.8M in market capitalization; recent performance reads 1-month -3.82% and YTD +3.54%.
The latest financial table shown here is Q1 2026, with revenue of $45.2M, net income of $4.1M, and EPS of $0.07. Investors can compare that operating picture with valuation signals such as P/E 24.16 and FCF yield 3.9%.
The latest indexable market news headline is "Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $11.00; recent insider activity includes Botzer Uri filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
24.16
PEG
0.60
P/B
1.66
P/S
2.32
EV/EBITDA
10.46
DCF Value
$39.44
FCF Yield
3.9%
Div Yield
3.4%
Margins & Returns
Gross Margin
41.2%
Operating Margin
14.0%
Net Margin
11.2%
ROE
7.7%
ROA
5.3%
ROIC
7.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $45.2M | $4.1M | $0.07 |
| Q4 2025 | $44.7M | $3.6M | $0.06 |
| FY 2025 | $180.5M | $20.2M | $0.37 |
| Q3 2025 | $47.0M | $5.3M | $0.09 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$11.00
Target (Median)
$11.00
Target Range
$11.00 - $11.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
IL
Exchange
—
Beta
0.15
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.